메뉴 건너뛰기




Volumn 34, Issue 5, 2006, Pages 836-847

Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXYTACROLIMUS; 13 O NORTACROLIMUS; 15 O NORTACROLIMUS; 31 O NORTACROLIMUS; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; RECOMBINANT ENZYME; TACROLIMUS; UNCLASSIFIED DRUG;

EID: 33645864935     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.008680     Document Type: Article
Times cited : (264)

References (40)
  • 1
    • 0031712063 scopus 로고    scopus 로고
    • Cyclosporin nephrotoxicity: Pathophysiology and comparison with FK-506
    • Ader JL and Rostaing L (1998) Cyclosporin nephrotoxicity: pathophysiology and comparison with FK-506. Curr Opin Nephrol Hypertens 7:539-545.
    • (1998) Curr Opin Nephrol Hypertens , vol.7 , pp. 539-545
    • Ader, J.L.1    Rostaing, L.2
  • 2
    • 0024412071 scopus 로고
    • Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine
    • Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV, et al. (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 264:10388 -10395.
    • (1989) J Biol Chem , vol.264 , pp. 10388-10395
    • Aoyama, T.1    Yamano, S.2    Waxman, D.J.3    Lapenson, D.P.4    Meyer, U.A.5    Fischer, V.6    Tyndale, R.7    Inaba, T.8    Kalow, W.9    Gelboin, H.V.10
  • 4
    • 0027516405 scopus 로고
    • Preparative chromatographic purification of cyclosporine metabolites
    • Brooks CA, Cramer SM, and Rosano TG (1993) Preparative chromatographic purification of cyclosporine metabolites. Clin Chem 39:457-466.
    • (1993) Clin Chem , vol.39 , pp. 457-466
    • Brooks, C.A.1    Cramer, S.M.2    Rosano, T.G.3
  • 7
    • 0033023568 scopus 로고    scopus 로고
    • FK506 nephrotoxicity
    • Finn WF (1999) FK506 nephrotoxicity. Renal Fail 21:319-329.
    • (1999) Renal Fail , vol.21 , pp. 319-329
    • Finn, W.F.1
  • 11
    • 0033668287 scopus 로고    scopus 로고
    • Potentiation by nitric oxide of cyclosporin A and FK506-induced apoptosis in renal proximal tubule cells
    • Hortelano S, Castilla M, Torres AM, Tejedor A, and Bosca L (2000) Potentiation by nitric oxide of cyclosporin A and FK506-induced apoptosis in renal proximal tubule cells. J Am Soc Nephrol 11:2315-2323.
    • (2000) J Am Soc Nephrol , vol.11 , pp. 2315-2323
    • Hortelano, S.1    Castilla, M.2    Torres, A.M.3    Tejedor, A.4    Bosca, L.5
  • 20
    • 0000574406 scopus 로고    scopus 로고
    • Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites
    • Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
    • (1998) Biochemistry , vol.37 , pp. 4137-4147
    • Korzekwa, K.R.1    Krishnamachary, N.2    Shou, M.3    Ogai, A.4    Parise, R.A.5    Rettie, A.E.6    Gonzalez, F.J.7    Tracy, T.S.8
  • 21
    • 6944230851 scopus 로고    scopus 로고
    • The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients
    • Kreutz R, Zurcher H, Kain S, Martus P, Offermann G, and Beige J (2004) The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 14:665-671.
    • (2004) Pharmacogenetics , vol.14 , pp. 665-671
    • Kreutz, R.1    Zurcher, H.2    Kain, S.3    Martus, P.4    Offermann, G.5    Beige, J.6
  • 23
    • 0037131879 scopus 로고    scopus 로고
    • Genetic contribution to variable human CYP3A-mediated metabolism
    • Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294.
    • (2002) Adv Drug Deliv Rev , vol.54 , pp. 1271-1294
    • Lamba, J.K.1    Lin, Y.S.2    Schuetz, E.G.3    Thummel, K.E.4
  • 25
    • 0034853228 scopus 로고    scopus 로고
    • In vitro immunosuppressive activity of tacrolimus dihydrodiol precursors obtained by chemical oxidation and identification of a new metabolite of SDZ-RAD by electrospray and electrospray-linked scan mass spectrometry
    • Lhoest G, Hertsens R, Verbeeck RK, Maton N, Wallemacq P, Dehoux JP, and Latinne D (2001) In vitro immunosuppressive activity of tacrolimus dihydrodiol precursors obtained by chemical oxidation and identification of a new metabolite of SDZ-RAD by electrospray and electrospray-linked scan mass spectrometry. J Mass Spectrom 36:889-901.
    • (2001) J Mass Spectrom , vol.36 , pp. 889-901
    • Lhoest, G.1    Hertsens, R.2    Verbeeck, R.K.3    Maton, N.4    Wallemacq, P.5    Dehoux, J.P.6    Latinne, D.7
  • 30
    • 0028204924 scopus 로고
    • Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes
    • Nagase K, Iwasaki K, Nozaki K, and Noda K (1994) Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J Pharm Pharmacol 46:113-117.
    • (1994) J Pharm Pharmacol , vol.46 , pp. 113-117
    • Nagase, K.1    Iwasaki, K.2    Nozaki, K.3    Noda, K.4
  • 31
    • 0034835463 scopus 로고    scopus 로고
    • Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans
    • Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, and Sugiyama Y (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316 -1324.
    • (2001) Drug Metab Dispos , vol.29 , pp. 1316-1324
    • Naritomi, Y.1    Terashita, S.2    Kimura, S.3    Suzuki, A.4    Kagayama, A.5    Sugiyama, Y.6
  • 32
    • 0035987898 scopus 로고    scopus 로고
    • Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach
    • Obach RS and Reed-Hagen AE (2002) Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 30:831-837.
    • (2002) Drug Metab Dispos , vol.30 , pp. 831-837
    • Obach, R.S.1    Reed-Hagen, A.E.2
  • 35
    • 0026662551 scopus 로고
    • Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat
    • Sattler M, Guengerich FP, Yun CH, Christians U, and Sewing KF (1992) Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 20:753-761.
    • (1992) Drug Metab Dispos , vol.20 , pp. 753-761
    • Sattler, M.1    Guengerich, F.P.2    Yun, C.H.3    Christians, U.4    Sewing, K.F.5
  • 36
    • 0038237028 scopus 로고    scopus 로고
    • Tacrolimus: A further update of its use in the management of organ transplantation
    • Scott LJ, McKeage K, Keam SJ, and Plosker GL (2003) Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 63:1247-1297.
    • (2003) Drugs , vol.63 , pp. 1247-1297
    • Scott, L.J.1    McKeage, K.2    Keam, S.J.3    Plosker, G.L.4
  • 37
    • 0028295725 scopus 로고
    • Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes
    • Shiraga T, Matsuda H, Nagase K, Iwasaki K, Noda K, Yamazaki H, Shimada T, and Funae Y (1994) Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol 47:727-735.
    • (1994) Biochem Pharmacol , vol.47 , pp. 727-735
    • Shiraga, T.1    Matsuda, H.2    Nagase, K.3    Iwasaki, K.4    Noda, K.5    Yamazaki, H.6    Shimada, T.7    Funae, Y.8
  • 38
    • 0242332169 scopus 로고    scopus 로고
    • Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients
    • Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, and Daly AK (2003) Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76:1233-1235.
    • (2003) Transplantation , vol.76 , pp. 1233-1235
    • Thervet, E.1    Anglicheau, D.2    King, B.3    Schlageter, M.H.4    Cassinat, B.5    Beaune, P.6    Legendre, C.7    Daly, A.K.8
  • 39
    • 0024521323 scopus 로고
    • Isolation, characterization and in vitro activity of human cyclosporin A metabolites
    • Wallemacq PE, Lhoest G, Latinne D, and De Bruyere M (1989) Isolation, characterization and in vitro activity of human cyclosporin A metabolites. Transplant Proc 21:906-910.
    • (1989) Transplant Proc , vol.21 , pp. 906-910
    • Wallemacq, P.E.1    Lhoest, G.2    Latinne, D.3    De Bruyere, M.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.